pH-responsive high-density lipoprotein-like nanoparticles to release paclitaxel at acidic pH in cancer chemotherapy

International Journal of Nanomedicine

Volumn 7, Issue , 2012, Pages 2805-2816

  Shin, Jae Yoon ^a   Yang, Yoosoo ^a   Heo, Paul ^a   Lee, Ji Chun ^a   Kong, ByoungJae ^a   Cho, Jae Youl ^a   Yoon, Keejung ^a   Shin, Cheol Su ^b   Seo, Jin Ho ^c   Kim, Sung Gun ^d   Kweon, Dae Hyuk ^a  

^a Sungkyunkwan University   (South Korea)

^b APTech Research Center   (South Korea)

^c Seoul National University   (South Korea)

^d Youngdong University   (South Korea)

Author keywords

Apolipoprotein A I; Nanoparticle; Paclitaxel; pH responsiveness

Indexed keywords

APOLIPOPROTEIN A1; HIGH DENSITY LIPOPROTEIN LIKE NANOPARTICLE; NANOPARTICLE; PACLITAXEL; PHOSPHATIDYLCHOLINE; PHOSPHOLIPID; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CHEMOTHERAPY; CIRCULAR DICHROISM; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; DRUG POTENCY; DRUG RELEASE; DRUG STRUCTURE; NANOANALYSIS; PARTICLE SIZE; PH; PH MEASUREMENT; PROTEIN SECONDARY STRUCTURE; STRUCTURE ACTIVITY RELATION; STRUCTURE ANALYSIS; TEMPERATURE MEASUREMENT;

ANTINEOPLASTIC AGENTS; APOLIPOPROTEIN A-I; CELL LINE, TUMOR; CELL SURVIVAL; DRUG CARRIERS; DRUG STABILITY; HUMANS; HYDROGEN-ION CONCENTRATION; MOLECULAR CONFORMATION; NANOPARTICLES; PACLITAXEL; PARTICLE SIZE; RECEPTOR, ERBB-2; RECOMBINANT PROTEINS;

EID: 84866537640     PISSN: 11769114     EISSN: 11782013     Source Type: Journal    
DOI: 10.2147/IJN.S29817     Document Type: Article

References (37)

1. Helmlinger G, Yuan F, Dellian M, Jain RK. Interstitial pH and pO2gradients in solid tumors in vivo: high-resolution measurements reveal a lack of correlation. Nat Med. 1997;3:177-182.
2. Wike-Hooley JL, Van der Zee J, van Rhoon GC, Van den Berg AP, Reinhold HS. Human tumour pH changes following hyperthermia and radiation therapy. Eur J Cancer Clin Oncol. 1984;20:619-623.
3. Shen Y, Tang H, Radosz M, Van Kirk E, Murdoch WJ. pH-responsive nanoparticles for cancer drug delivery. Methods Mol Biol. 2008;437: 183-216.
4. Ganta S, Devalapally H, Shahiwala A, Amiji M. A review of stimuli-responsive nanocarriers for drug and gene delivery. J Control Release. 2008;126:187-204.
5. Onaca O, Enea R, Hughes DW, Meier W. Stimuli-responsive polymersomes as nanocarriers for drug and gene delivery. Macromol Biosci. 2009;9:129-139.
6. Connor J, Yatvin MB, Huang L. pH-sensitive liposomes: acid-induced liposome fusion. Proc Natl Acad Sci U S A. 1984;81:1715-1718.
7. Bae Y, Nishiyama N, Fukushima S, Koyama H, Yasuhiro M, Kataoka K. Preparation and biological characterization of polymeric micelle drug carriers with intracellular pH-triggered drug release property: tumor permeability, controlled subcellular drug distribution, and enhanced in vivo antitumor efficacy. Bioconjug Chem. 2005;16:122-130.
8. Oh KT, Kim D, You HH, Ahn YS, Lee ES. pH-sensitive properties of surface charge-switched multifunctional polymeric micelle. Int J Pharm. 2009;376:134-140.
9. Bae Y, Fukushima S, Harada A, Kataoka K. Design of environment-sensitive supramolecular assemblies for intracellular drug delivery: polymeric micelles that are responsive to intracellular pH change. Angew Chem Int Ed Engl. 2003;42:4640-4643.
10. Ng KK, Lovell JF, Zheng G. Lipoprotein-inspired nanoparticles for cancer theranostics. Acc Chem Res. 2011;44:1105-1113.
11. Ryan RO. Nanobiotechnology applications of reconstituted high density lipoprotein. J Nanobiotechnology. 2010;8:28.
12. Mooberry LK, Nair M, Paranjape S, McConathy WJ, Lacko AG. Receptor mediated uptake of paclitaxel from a synthetic high density lipoprotein nanocarrier. J Drug Target. 2010;18:53-58.
13. Cao W, Ng KK, Corbin I, etal. Synthesis and evaluation of a stable bacteriochlorophyll analog and its incorporation into high-density lipoprotein nanoparticles for tumor imaging. Bioconjug Chem. 2009;20: 2023-2031.
14. Pussinen PJ, Karten B, Wintersperger A, etal. The human breast carcinoma cell line HBL-100 acquires exogenous cholesterol from high-density lipoprotein via CLA-1 (CD-36 and LIMPII analogous 1)-mediated selective cholesteryl ester uptake. Biochem J. 2000;349:559-566.
15. Singla AK, Garg A, Aggarwal D. Paclitaxel and its formulations. Int J Pharm. 2002;235:179-192.
16. Davidson WS, Hazlett T, Mantulin WW, Jonas A. The role of apolipoprotein AI domains in lipid binding. Proc Natl Acad Sci U S A. 1996;93:13605-13610.
17. Jayaraman S, Benjwal S, Gantz DL, Gursky O. Effects of cholesterol on thermal stability of discoidal high density lipoproteins. J Lipid Res. 2010;51:324-333.
18. Ryan RO, Forte TM, Oda MN. Optimized bacterial expression of human apolipoprotein A-I. Protein Expr Purif. 2003;27:98-103.
19. Shin JY, Shin JI, Kim JS, etal. Assembly of Coenzyme Q10 nanostructure resembling nascent discoidal high density lipoprotein particle. Biochem Biophys Res Commun. 2009;388:217-221.
20. Lacko AG, Nair M, Paranjape S, Johnso S, McConathy WJ. High density lipoprotein complexes as delivery vehicles for anticancer drugs. Anticancer Res. 2002;22:2045-2049.
21. McConathy WJ, Nair MP, Paranjape S, Mooberry L, Lacko AG. Evaluation of synthetic/reconstituted high-density lipoproteins as delivery vehicles for paclitaxel. Anticancer Drugs. 2008;19:183-188.
22. Ghosh M, Singh AT, Xu W, Sulchek T, Gordon LI, Ryan RO. Curcumin nanodisks: formulation and characterization. Nanomedicine. 2011;7:162-167.
23. Redmond KA, Nguyen TS, Ryan RO. All-trans-retinoic acid nanodisks. Int J Pharm. 2007;339:246-250.
24. Tufteland M, Ren G, Ryan RO. Nanodisks derived from amphotericin B lipid complex. J Pharm Sci. 2008;97:4425-4432.
25. Ewert KK, Ahmad A, Bouxsein NF, Evans HM, Safinya CR. Non-viral gene delivery with cationic liposome-DNA complexes. Methods Mol Biol. 2008;433:159-175.
26. Huang X, Caddell R, Yu B, etal. Ultrasound-enhanced microfluidic synthesis of liposomes. Anticancer Res. 2010;30:463-466.
27. Gao W, Chan JM, Farokhzad OC. pH-Responsive nanoparticles for drug delivery. Mol Pharm. 2010;7:1913-1920.
28. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science. 1987;235:177-182.
29. Holmes FA, Walters RS, Theriault RL, etal. Phase II trial of Taxol, an active drug in the treatment of metastatic breast cancer. J Natl Cancer Inst. 1991;83:1797-1805.
30. Wahl AF, Donaldson KL, Fairchild C, etal. Loss of normal p53 function confers sensitization to Taxol by increasing G2/M arrest and apoptosis. Nat Med. 1996;2:72-79.
31. Yu D, Jing T, Liu B, etal. Overexpression of ErbB2 blocks Taxol-induced apoptosis by upregulation of p21Cip1, which inhibits p34Cdc2 kinase. Mol Cell. 1998;2:581-591.
32. Orjalo A, Johansson HE, Ruth JL. Stellaris[trade] fluorescence in situ hybridization (FISH) probes: a powerful tool for mRNA detection. Nat Meth. 8.
33. Lattrich C, Juhasz-Boess I, Ortmann O, Treeck O. Detection of an elevated HER2 expression in MCF-7 breast cancer cells overexpressing estrogen receptor beta1. Oncol Rep. 2008;19:811-817.
34. Tuna M, Chavez-Reyes A, Tari AM. HER2/neu increases the expression of Wilms' tumor 1 (WT1) protein to stimulate S-phase proliferation and inhibit apoptosis in breast cancer cells. Oncogene. 2005;24:1648-1652.
35. Dominska M, Dykxhoorn DM. Breaking down the barriers: siRNA delivery and endosome escape. J Cell Sci. 2010;123:1183-1189.
36. Sparks DL, Lund-Katz S, Phillips MC. The charge and structural stability of apolipoprotein A-I in discoidal and spherical recombinant high density lipoprotein particles. J Biol Chem. 1992;267:25839-25847.
37. Varkouhi AK, Scholte M, Storm G, Haisma HJ. Endosomal escape pathways for delivery of biologicals. J Control Release. 2011;151:220-228.